PMID- 36291857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221030
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 20
DP  - 2022 Oct 17
TI  - Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved 
      Treatments with Transplant Oncology Vision.
LID - 10.3390/cancers14205074 [doi]
LID - 5074
AB  - A minority of cholangiocarcinoma (CCA) can be cured by surgical intervention 
      (i.e., liver resection (LR) and liver transplantation (LT)). When modern criteria 
      for LT are met, this intervention along with neoadjuvant treatments may achieve 
      unprecedented survival in selected patients. Liver resection is associated with a 
      median overall survival (OS) of 40 months, this number drastically decreases for 
      unresectable advanced cholangiocarcinoma (CCA), which is treated with systemic 
      therapy. The first-line chemotherapy regimen of gemcitabine and cisplatin is 
      associated with a median overall survival of only 11.7 months. Since the Food and 
      Drug Administration (FDA)'s approval of the isocitrate dehydrogenase (IDH) 1 
      inhibitor ivosidenib in August 2021, there has been increasing interest in 
      targeted therapy for CCA patients harboring mutations in fibroblast growth factor 
      receptor (FGFR) 2, neurotrophic receptor tyrosine kinase (NTRK), B-raf kinase 
      (BRAF), and HER2. At the same time, immunotherapy with immune checkpoint 
      inhibitors isalso being used in relapsed CCA. This review looks into the most 
      recently completed and ongoing studies of targeted therapy as monotherapy or in 
      combination with chemo- and/or immunotherapy. Whether it is resection, liver 
      transplant, radiotherapy, chemotherapy, immunotherapy, targeted therapy, or any 
      combination of these treatment modalities, great strides are being made to 
      improve outcomes for this challenging disease.
FAU - Zhang, Yuqi
AU  - Zhang Y
AD  - Department of Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.
FAU - Esmail, Abdullah
AU  - Esmail A
AUID- ORCID: 0000-0002-2337-8351
AD  - Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer 
      Center, Houston, TX 77030, USA.
AD  - Cancer Clinical Trials, Houston Methodist Research Institute, Houston, TX 77030, 
      USA.
FAU - Mazzaferro, Vincenzo
AU  - Mazzaferro V
AD  - Department of Oncology, University of Milan, 20133 Milan, Italy.
AD  - Gastro-Intestinal Surgery and Liver Transplantation Unit, The Instituto Nazionale 
      Tumori (National Cancer Institute) of Milan, 20133 Milan, Italy.
FAU - Abdelrahim, Maen
AU  - Abdelrahim M
AD  - Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer 
      Center, Houston, TX 77030, USA.
AD  - Weill Cornell Medical College, New York, NY 14853, USA.
AD  - Cockrell Center for Advanced Therapeutic Phase I program, Houston Methodist 
      Research Institute, Houston, TX 77030, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221017
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9600404
OTO - NOTNLM
OT  - cholangiocarcinoma
OT  - immunotherapy
OT  - targeted therapy
OT  - transplant oncology
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/10/17
CRDT- 2022/10/27 01:14
PHST- 2022/08/25 00:00 [received]
PHST- 2022/10/09 00:00 [revised]
PHST- 2022/10/12 00:00 [accepted]
PHST- 2022/10/27 01:14 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/10/17 00:00 [pmc-release]
AID - cancers14205074 [pii]
AID - cancers-14-05074 [pii]
AID - 10.3390/cancers14205074 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Oct 17;14(20):5074. doi: 10.3390/cancers14205074.